Induction and consolidation therapy
| . | Dose . | Time, d . |
|---|---|---|
| Prephase | ||
| Prednisone | 60 mg/m2/d PO | Between −7 and −1 |
| Methotrexate | 15 mg IT | Between −7 and −4 |
| Standard induction, wks 1-2 | ||
| Daunorubicin | 50 mg/m2/d IV | 1 to 3 |
| Cyclophosphamide | 750 mg/m2/d IV | 1 |
| Vincristine | 2 mg IV | 1, 8 |
| Prednisone | 60 mg/m2/d PO | 1 to 14 |
| L-asparaginase | 6000 IU/m2/d IV | 8, 10, 12 |
| Triple IT | —‡ | 1, 8 |
| Standard induction, wks 3-4 | ||
| Daunorubicin | 30 mg/m2/d IV | 15 to 16 |
| Cyclophosphamide | 750 mg/m2/d IV | 15 |
| Vincristine | 2 mg IV | 15, 22 |
| L-asparaginase | 6000 IU/m2/d IV | 20, 22, 24, 26, 28 |
| G-CSF lenograstim | 150 μg/m2/d SC or IV | From 17 |
| DIV combination* | ||
| Vincristine | 2 mg IV | 1, 8, 15, 22 |
| Dexamethasone | 40 mg PO or IV | 1-2, 8-9, 15-16, 22-23 |
| Imatinib | 800 mg/d PO | 1 until SCT |
| Triple IT | —‡ | 1, 8, 15, 22 |
| HAMI combination† | ||
| Mitoxantrone | 10 mg/m2/d, IV | 1 to 3 |
| Cytarabine | 2000 mg/m2/12h, IV | 1 to 4 |
| Imatinib | 600 mg/d PO | 1 until SCT |
| Triple IT | —‡ | 8, 15 |
| G-CSF filgrastim | 5 μg/kg/d SC or IV | From 9 |
| . | Dose . | Time, d . |
|---|---|---|
| Prephase | ||
| Prednisone | 60 mg/m2/d PO | Between −7 and −1 |
| Methotrexate | 15 mg IT | Between −7 and −4 |
| Standard induction, wks 1-2 | ||
| Daunorubicin | 50 mg/m2/d IV | 1 to 3 |
| Cyclophosphamide | 750 mg/m2/d IV | 1 |
| Vincristine | 2 mg IV | 1, 8 |
| Prednisone | 60 mg/m2/d PO | 1 to 14 |
| L-asparaginase | 6000 IU/m2/d IV | 8, 10, 12 |
| Triple IT | —‡ | 1, 8 |
| Standard induction, wks 3-4 | ||
| Daunorubicin | 30 mg/m2/d IV | 15 to 16 |
| Cyclophosphamide | 750 mg/m2/d IV | 15 |
| Vincristine | 2 mg IV | 15, 22 |
| L-asparaginase | 6000 IU/m2/d IV | 20, 22, 24, 26, 28 |
| G-CSF lenograstim | 150 μg/m2/d SC or IV | From 17 |
| DIV combination* | ||
| Vincristine | 2 mg IV | 1, 8, 15, 22 |
| Dexamethasone | 40 mg PO or IV | 1-2, 8-9, 15-16, 22-23 |
| Imatinib | 800 mg/d PO | 1 until SCT |
| Triple IT | —‡ | 1, 8, 15, 22 |
| HAMI combination† | ||
| Mitoxantrone | 10 mg/m2/d, IV | 1 to 3 |
| Cytarabine | 2000 mg/m2/12h, IV | 1 to 4 |
| Imatinib | 600 mg/d PO | 1 until SCT |
| Triple IT | —‡ | 8, 15 |
| G-CSF filgrastim | 5 μg/kg/d SC or IV | From 9 |
PO indicates per os (orally); IT, intrathecally; IV, intravenously; SC, subcutaneously.
Administered at day 15 of the standard induction course in patients with corticoresistant and/or chemoresistant ALL.
Administered after hematologic CR achievement as consolidation in patients with corticosensitive and chemosensitive ALL.
Consisted of 15 mg methotrexate, 40 mg cytarabine, and 40 mg dexamethasone, all administered intrathecally.